Business Context and Reporting Period
This Form 8-K filing by Moderna, Inc. (MRNA) is dated February 12, 2020. The report announces the scheduling of the Company's 2020 Annual Meeting of Stockholders and establishes revised deadlines for stockholder proposals and director nominations.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding corporate governance and shareholder meeting logistics, not a financial results announcement.
Material Changes
The primary material change is the scheduling of the 2020 Annual Meeting for April 29, 2020. This date differs by more than thirty days from the anniversary of the 2019 Annual Meeting (June 27, 2019). Consequently, the standard deadlines for stockholder proposals under Rule 14a-8 and director nominations are no longer applicable, necessitating the establishment of new deadlines.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or management commentary regarding business operations. The document focuses exclusively on the procedural requirements for the upcoming Annual Meeting, including:
- Meeting Date: Wednesday, April 29, 2020, at 8:00 a.m. Eastern Time.
- Location: 200 Technology Square, Cambridge, Massachusetts.
- Record Date: Close of business on Monday, March 2, 2020.
- Proposal Deadline: Stockholder proposals and director nominations must be received by the Corporate Secretary by the close of business on Monday, February 24, 2020.
Key Facts for Investor Verification
- Verify the record date of March 2, 2020, to determine eligibility to vote at the 2020 Annual Meeting.
- Confirm the strict deadline of February 24, 2020, for submitting any stockholder proposals or director nominations for inclusion in the proxy materials.
- Note that the meeting date shift invalidates the standard Rule 14a-8 deadlines, requiring adherence to the specific dates outlined in this 8-K.
